Madrigal Pharmaceuticals plans to release Q3 2025 financial results on November 4, with a webcast at 8 a.m. ET.
Quiver AI Summary
Madrigal Pharmaceuticals, Inc. announced that it will release its third-quarter 2025 financial results on November 4, 2025, before the U.S. markets open. Following this announcement, the company's management will hold a live webcast at 8 a.m. Eastern Time to discuss the financial and operating results, which can be accessed on their website. Madrigal is focused on developing treatments for metabolic dysfunction-associated steatohepatitis (MASH), with their drug Rezdiffra being the first approved therapy for MASH with moderate to advanced fibrosis. They are currently conducting a Phase 3 trial for Rezdiffra's use in compensated MASH cirrhosis.
Potential Positives
- Madrigal Pharmaceuticals is set to announce its third-quarter 2025 financial results, which may provide key insights into the company's financial health and progress in its operations.
- The company is hosting a live webcast for investors to review financial and operating results, promoting transparency and engagement with stakeholders.
- Madrigal's medication, Rezdiffra, is the first and only FDA and European Commission approved treatment for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis, highlighting the company's innovative contributions to addressing a high unmet medical need.
- The ongoing Phase 3 outcomes trial for Rezdiffra marks a significant step in the development of treatments for compensated MASH cirrhosis, potentially expanding the market for their product.
Potential Negatives
- Failure to disclose any financial performance metrics in the upcoming quarterly results may lead to investor uncertainty and decreased confidence in the company's financial health.
- The announcement does not provide any updates on the ongoing Phase 3 trial, which may raise concerns about the progress of their leading therapeutic candidate, Rezdiffra.
- Absence of specific milestones or achievements related to MASH treatment progress might suggest stagnation or lack of advancements, affecting stakeholder perception.
FAQ
When will Madrigal Pharmaceuticals release its third-quarter 2025 financial results?
Madrigal Pharmaceuticals will release its third-quarter 2025 financial results on Tuesday, Nov. 4, 2025, before U.S. market opens.
How can I participate in the Madrigal Pharmaceuticals webcast?
Participants can access the live webcast via the Investor Relations section of the Madrigal Pharmaceuticals website.
What is Rezdiffra and what condition does it treat?
Rezdiffra (resmetirom) is a medication for metabolic dysfunction-associated steatohepatitis (MASH), specifically for patients with moderate to advanced fibrosis.
What is the ongoing clinical trial for Rezdiffra?
An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c).
Who should I contact for investor or media inquiries regarding Madrigal Pharmaceuticals?
For investor inquiries, contact Tina Ventura at [email protected]. For media inquiries, contact Christopher Frates at [email protected].
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MDGL Insider Trading Activity
$MDGL insiders have traded $MDGL stock on the open market 132 times in the past 6 months. Of those trades, 54 have been purchases and 78 have been sales.
Here’s a breakdown of recent trading of $MDGL stock by insiders over the last 6 months:
- PAUL A FRIEDMAN has made 0 purchases and 39 sales selling 206,256 shares for an estimated $75,145,423.
- BROS. ADVISORS LP BAKER has made 54 purchases buying 165,683 shares for an estimated $61,921,024 and 0 sales.
- REBECCA TAUB has made 0 purchases and 22 sales selling 76,564 shares for an estimated $27,137,134.
- WILLIAM JOHN SIBOLD (President and CEO) has made 0 purchases and 3 sales selling 14,895 shares for an estimated $6,291,497.
- KENNETH BATE has made 0 purchases and 6 sales selling 10,000 shares for an estimated $3,652,008.
- SHANNON T KELLEY (General Counsel) has made 0 purchases and 8 sales selling 1,304 shares for an estimated $479,626.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MDGL Hedge Fund Activity
We have seen 146 institutional investors add shares of $MDGL stock to their portfolio, and 158 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HOLOCENE ADVISORS, LP removed 390,545 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $118,194,538
- FMR LLC removed 206,760 shares (-31.7%) from their portfolio in Q2 2025, for an estimated $62,573,846
- CITADEL ADVISORS LLC added 206,538 shares (+25785.0%) to their portfolio in Q2 2025, for an estimated $62,506,660
- VANGUARD GROUP INC added 187,170 shares (+11.1%) to their portfolio in Q2 2025, for an estimated $56,645,128
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 184,554 shares (+96.3%) to their portfolio in Q2 2025, for an estimated $55,853,422
- UBS GROUP AG added 184,207 shares (+57.3%) to their portfolio in Q2 2025, for an estimated $55,748,406
- WOODLINE PARTNERS LP removed 157,810 shares (-49.7%) from their portfolio in Q2 2025, for an estimated $47,759,618
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$MDGL Analyst Ratings
Wall Street analysts have issued reports on $MDGL in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 10/15/2025
- Oppenheimer issued a "Outperform" rating on 10/10/2025
- B. Riley Securities issued a "Buy" rating on 09/29/2025
- Canaccord Genuity issued a "Buy" rating on 09/12/2025
- TD Cowen issued a "Buy" rating on 08/26/2025
- UBS issued a "Buy" rating on 08/12/2025
To track analyst ratings and price targets for $MDGL, check out Quiver Quantitative's $MDGL forecast page.
$MDGL Price Targets
Multiple analysts have issued price targets for $MDGL recently. We have seen 9 analysts offer price targets for $MDGL in the last 6 months, with a median target of $540.0.
Here are some recent targets:
- Yasmeen Rahimi from Piper Sandler set a target price of $540.0 on 10/15/2025
- Srikripa Devarakonda from Truist Securities set a target price of $580.0 on 10/15/2025
- Jay Olson from Oppenheimer set a target price of $590.0 on 10/10/2025
- Mayank Mamtani from B. Riley Securities set a target price of $560.0 on 09/29/2025
- Edward Nash from Canaccord Genuity set a target price of $526.0 on 09/12/2025
- Andrew S. Fein from HC Wainwright & Co. set a target price of $500.0 on 09/04/2025
- Ritu Baral from TD Cowen set a target price of $554.0 on 08/26/2025
Full Release
CONSHOHOCKEN, Pa., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today that it will release its third-quarter 2025 financial results on Tuesday, Nov. 4, 2025, prior to the open of the U.S. financial markets.
Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.
The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website . To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
The webcast will be available approximately two hours after the live webcast.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit
www.madrigalpharma.com
.
Investor Contact
Tina Ventura,
[email protected]
Media Contact
Christopher Frates,
[email protected]